Cantor maintains Overweight rating on Mereo BioPharma stock

On Thursday, Cantor Fitzgerald analysts reaffirmed their Overweight rating on Mereo BioPharma Group (NASDAQ:MREO) shares, maintaining a price target of $7.00. Currently trading at $2.37, near its 52-week low of $2.22, the stock shows significant upside potential according to analysts, with targets ranging from $5.98 to $10.01. The decision follows a comprehensive review of the company’s financial model for the full year, taking into account the latest operating expense estimates provided by Mereo BioPharma’s guidance. InvestingPro data reveals the company maintains strong liquidity with a current ratio of 5.4.

The analysts at Cantor Fitzgerald have adjusted their model to reflect the company’s anticipated expenses, ensuring that their projections are aligned with the information shared by Mereo BioPharma. Despite these updates to the operating costs, the analysts have made no changes to their 12-month price target for the biopharmaceutical company’s stock. InvestingPro analysis indicates the company holds more cash than debt on its balance sheet, though it’s currently not profitable with an EBITDA of -$45.13M. Discover 8 more exclusive InvestingPro Tips and comprehensive financial analysis in the Pro Research Report.

The Overweight rating indicates the analysts’ expectation that Mereo BioPharma’s stock will perform better than the average return of the stocks analyzed by Cantor Fitzgerald over the next 12 months. The $7.00 price target suggests a level of confidence in the company’s potential to reach this valuation within the specified time frame.

Mereo BioPharma Group specializes in developing and commercializing innovative therapies intended to address unmet medical needs. The reiteration of the Overweight rating and price target by Cantor Fitzgerald underscores the firm’s ongoing belief in the strength and potential of Mereo BioPharma’s business and financial strategies.

Investors and market watchers typically monitor such ratings and price targets as indicators of market sentiment and the potential future performance of a company’s shares. The affirmation of the rating and price target by Cantor Fitzgerald provides a point of reference for those interested in Mereo BioPharma’s stock market activity.

In other recent news, Mereo BioPharma Group has garnered attention with its ongoing clinical trials and financial outlook. JPMorgan initiated coverage on Mereo BioPharma with an Overweight rating and a $7.00 price target, driven by the promising data from the phase 3 trials of setrusumab for osteogenesis imperfecta (OI). The trials, ORBIT and COSMIC, are expected to yield significant results, with analysts expressing strong conviction in their success. BTIG also maintained a Buy rating, noting the company’s financial stability with $69.8 million in cash, which is expected to support operations into 2027. Analysts at BTIG highlighted a 90% probability of success for setrusumab, emphasizing the drug’s promising safety and efficacy profile from earlier trials.

Cantor Fitzgerald echoed these sentiments, maintaining an Overweight rating and a $7.00 price target, focusing on setrusumab’s potential in reducing fractures. The firm’s analysts noted that even if the primary endpoint is not achieved, the drug could still be deemed clinically meaningful with a 30-35% reduction in fractures. Insights from a recent webinar with the Osteogenesis Imperfecta Foundation further underscored the high conviction in setrusumab’s mechanism and data. Both Ultragenyx (NASDAQ:RARE) and Mereo BioPharma remain top picks for Cantor Fitzgerald, with a positive outlook on their collaborative efforts. As these developments unfold, stakeholders are closely monitoring the progress of setrusumab, which could offer a new treatment option for those affected by OI.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.